Eradication of Helicobacter pylori in Patients with Inflammatory Bowel Disease for Prevention of Recurrences - Impact on the Natural History of the Disease

Varas, Modesto; Muñoz Agel, Fernando; Sánchez-Vizcaíno Mengual, Elena

doi:10.14744/ejmo.2018.0058

Eradication of Helicobacter pylori in Patients with Inflammatory Bowel Disease for Prevention of Recurrences - Impact on the Natural History of the Disease

Modesto LORENZO, (Hospital Sanitas CIMA, Department of Gastroenterology, Barcelona, Spain)

Fernando AGEL, (Endoscopy Unit and Department of Gastroenterology Hospital Sanitas CIMA, Barcelona, Spain)

Elena MENGUAL (Medical Writing and Research Projects Management, Santa Coloma de Gramanet, Barcelona, Spain)

Eurasian Journal of Medicine and Oncology

4 0

Yıl: 2019 Cilt: 3 Sayı: 1 Sayfa Aralığı: 59 - 65 Metin Dili: İngilizce DOI: 10.14744/ejmo.2018.0058 İndeks Tarihi: 22-04-2020

Eradication of Helicobacter pylori in Patients with Inflammatory Bowel Disease for Prevention of Recurrences - Impact on the Natural History of the Disease

Öz:

Objectives: Although, currently, it turns to speculate on infectious etiology of Crohn’s disease (CD), many studies haveattributed a lower prevalence of Helicobacter pylori infection in patients with inflammatory bowel disease (IBD). The aimof this retrospective study was determining the benefit of detection and eradication of H. pylori in patients with IBD andits potential impact on the natural history of the disease.Methods: Retrospective study of 125 patients: 20 of the control group and 105 with gastrointestinal disorders. The 13Curea breath test was required as a routine procedure for all patients before receiving any dose of sulfasalazine.Results: Case group had an average of infection with H. pylori (42%), similar to the control group (40%). IBD showeda similar positivity to 13C-urea breath test (OR=0.99; 95% CI: 0.32–3.05). Higher incidence was found in microscopiccolitis (46%) and CD (52%), than in ulcerative colitis (40%), without substantial differences. Patients treated for H. pylori,reduced the number of recurrences.Conclusion: The eradication of H. pylori in patients with IBD may have a positive impact on the natural history of thedisease, although more prospective studies are needed.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Püspök A, Dejaco C, Oberhuber G, Waldhör T, Hirschl AM, Vogelsang H, et al. Influence of helicobacter pylori infection on the phenotype of Crohn’s disease-a frequent type of gastritis in patients with Crohn’s disease. Am J Gastroenterol 1999;94:3239–44.
2. Mantzaris GJ, Archavlis E, Zografos C, Zavos K, Petraki K, Triadaphyllou G. Low prevalence of Helicobacter pylori in inflammatory bowel disease: Association with sulfasalazine. Am J Gastroenterol 1995;90:1900.
3. el-Omar E, Penman I, Cruikshank G, Dover S, Banerjee S, Williams C, et al. Low prevalence of helicobacter pylori in inflammatory bowel disease: Association with sulphasalazine. Gut 1994;35:1385–8.
4. Halme L, Rautelin H, Leidenius M, Kosunen TU. Inverse correlation between helicobacter pylori infection and inflammatory bowel disease. J Clin Pathol 1996;49:65–7.
5. Wagtmans MJ, Witte AM, Taylor DR, Biemond I, Veenendaal RA, Verspaget HW, et al. Low seroprevalence of helicobacter pylori antibodies in historical sera of patients with Crohn’s disease. Scand J Gastroenterol 1997;32:712–8.
6. Väre PO, Heikius B, Silvennoinen JA, Karttunen R, Niemelä SE, Lehtola JK, et al. Seroprevalence of helicobacter pylori infection in inflammatory bowel disease: Is helicobacter pylori infection a protective factor? Scand J Gastroenterol 2001;36:1295–300.
7. Carrière J, Darfeuille-Michaud A, Nguyen HT. Infectious etiopathogenesis of Crohn’s disease. World J Gastroenterol 2014;20:12102–17.
8. Guslandi M, Fanti L, Testoni PA. Helicobacter pylori seroprevalence in Crohn’s disease: Lack of influence by pharmacological treatment. Hepatogastroenterology 2002;49:1296–7.
9. Ruuska T, Vaajalahti P, Arajärvi P, Mäki M. Prospective evaluation of upper gastrointestinal mucosal lesions in children with ulcerative colitis and Crohn’s disease. J Pediatr Gastroenterol Nutr 1994;19:181–6.
10. Oberhuber G, Hirsch M, Stolte M. High incidence of upper gastrointestinal tract involvement in Crohn’s disease. Virchows Arch 1998;432:49–52.
11. Kolho KL, Rautelin H, Lindahl H, Savilahti E. Helicobacter pylori-positive gastritis in pediatric patients with chronic inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1998;27:292–5.
12. D'Incà R, Sturniolo G, Cassaro M, di Pace C, Longo G, Callegari I, et al. Prevalence of upper gastrointestinal lesions and helicobacter pylori infection in Crohn’s disease. Dig Dis Sci 1998;43:988–92.
13. Matsumura M, Matsui T, Hatakeyama S, Matake H, Uno H, Sakurai T, et al. Prevalence of helicobacter pylori infection and correlation between severity of upper gastrointestinal lesions and H. Pylori infection in Japanese patients with Crohn’s disease. J Gastroenterol 2001;36:740–7.
14. Parlak E, Ulker A, Dişibeyaz S, Alkim C, Dağli U. There is no significant increase in the incidence of helicobacter pylori infection in patients with inflammatory bowel disease in Turkey. J Clin Gastroenterol 2001;33:87–8.
15. Kazuhiro M, Mitsuo O, Mitsuro S, Kunihiko A, Masashi Y, Shotao S. Evaluation of gastroduodenal mucosal lesions in patients with Crohn’s disease and ulcerative colitis. Dig Endosc 2004;16:3.
16. Sharif F, McDermott M, Dillon M, Drumm B, Rowland M, Imrie C, et al. Focally enhanced gastritis in children with Crohn’s disease and ulcerative colitis. Am J Gastroenterol 2002;97:1415–20.
17. Danelius M, Ost A, Lapidus AB. Inflammatory bowel diseaserelated lesions in the duodenal and gastric mucosa. Scand J Gastroenterol 2009;44:441–5.
18. Pearce CB, Duncan HD, Timmis L, Green JR. Assessment of the prevalence of infection with helicobacter pylori in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000;12:439–43.
19. Piodi LP, Bardella M, Rocchia C, Cesana BM, Baldassarri A, Quatrini M, et al. Possible protective effect of 5-aminosalicylic acid on helicobacter pylori infection in patients with inflammatory bowel disease. J Clin Gastroenterol 2003;36:22–5.
20. Prónai L, Schandl L, Orosz Z, Magyar P, Tulassay Z. Lower prevalence of helicobacter pylori infection in patients with inflammatory bowel disease but not with chronic obstructive pulmonary disease-antibiotic use in the history does not play a significant role. Helicobacter 2004;9:278–83.
21. Hwang SJ, Park D, Choi HS, Park JH, Kim HJ, Cho YK, et al. Prevalence of Helicobacter pylori infection in Korean patients with inflammatory bowel disease. Korean J Med 2006;71:267.
22. Ando T, Watanabe O, Ishiguro K, Maeda O, Ishikawa D, Minami M, et al. Relationships between helicobacter pylori infection status, endoscopic, histopathological findings, and cytokine production in the duodenum of Crohn’s disease patients. J Gastroenterol Hepatol 2008;23 Suppl 2:S193–7.
23. Oliveira AG, das Graças Pimenta Sanna M, Rocha GA, Rocha AM, Santos A, Dani R, et al. Helicobacter species in the intestinal mucosa of patients with ulcerative colitis. J Clin Microbiol 2004;42:384–6.
24. Song MJ, Park DI, Hwang SJ, Kim ER, Kim YH, Jang BI, et al. The prevalence of helicobacter pylori infection in Korean patients with inflammatory bowel disease, a multicenter study. Korean J Gastroenterol 2009;53:341–7.
25. Lorenzo MJ, Muñoz-Agel F. Existe una menor o mayor frecuencia de infección activa por Helicobacter pylori en pacientes con enfermedad de Crohn? Rev Esp Enferm Dig 2010;102:509–10.
26. Pellicano R, Bresso F, Demarchi B, Bertolusso L, Sapone N, Rizzetto M, et al. Prevalence of helicobacter pylori infection in patients with inflammatory bowel disease: Pilot study. Rev Esp Enferm Dig 2010;102:675–6.
27. Zhang S, Zhong B, Chao K, Xiao Y, Cui Y, Gao X, et al. Role of helicobacter species in Chinese patients with inflammatory bowel disease. J Clin Microbiol 2011;49:1987–9.
28. Luther J, Dave M, Higgins PD, Kao JY. Association between helicobacter pylori infection and inflammatory bowel disease: A meta-analysis and systematic review of the literature. Inflamm Bowel Dis 2010;16:1077–84.
29. Catalán JM, Rojas M, Gómez BJ. Menor prevalencia de infección por helicobacter pylori en pacientes con enfermedad inflamatoria intestinal. Rev Esp Enferm Dig 2007;8:S1130.
30. Xiang Z, Chen YP, Ye YF, Ma KF, Chen SH, Zheng L, et al. Helicobacter pylori and Crohn’s disease: A retrospective single-center study from China. World J Gastroenterol 2013;19:4576–81.
31. Jin X, Chen YP, Chen SH, Xiang Z. Association between helicobacter pylori infection and ulcerative colitis-a case control study from China. Int J Med Sci 2013;10:1479–84.
32. Bell SJ, Chisholm SA, Owen RJ, Borriello SP, Kamm MA. Evaluation of helicobacter species in inflammatory bowel disease. Aliment Pharmacol Ther 2003;18:481–6.
33. Bohr UR, Glasbrenner B, Primus A, Zagoura A, Wex T, Malfertheiner P, et al. Identification of enterohepatic helicobacter species in patients suffering from inflammatory bowel disease. J Clin Microbiol 2004;42:2766–8.
34. Streutker CJ, Bernstein CN, Chan VL, Riddell RH, Croitoru K. Detection of species-specific helicobacter ribosomal DNA in intestinal biopsy samples from a population-based cohort of patients with ulcerative colitis. J Clin Microbiol 2004;42:660–4.
35. Zhang L, Day A, McKenzie G, Mitchell H. Nongastric helicobacter species detected in the intestinal tract of children. J Clin Microbiol 2006;44:2276–9.
36. Sanna Md, Moura SB, Dani R, Marinho FP, Moreira LS, Ferrari Mde L, et al. Isolation of Helicobacter pylori from the intestinal mucosa of patients with Crohn’s disease. Helicobacter 2006;11:2–9.
37. Man SM, Zhang L, Day AS, Leach S, Mitchell H. Detection of enterohepatic and gastric helicobacter species in fecal specimens of children with Crohn’s disease. Helicobacter 2008;13:234–8.
38. Fallone CA, Bitton A. Is IBD caused by Helicobacter pylori infection? Inflamm Bowel Dis 2009;14:S37–8.
39. Man SM, Kaakoush NO, Mitchell HM. The role of bacteria and pattern-recognition receptors in Crohn’s disease. Nat Rev Gastroenterol Hepatol 2011;8:152–68.
40. Sartor RB. Does mycobacterium avium subspecies paratuberculosis cause Crohn’s disease? Gut 2005;54:896–8.
41. Abubakar I, Myhill D, Aliyu SH, Hunter PR. Detección de Mycobacterium avium subespecie paratuberculosis en pacientes con enfermedad de Crohn utilizando técnicas basadas en la detección de ácidos nucleicos: Una revisión sistemática y meta-análisis. Inflama Bowel Dis 2008;14:401–10.
42. Thomson JM, Hansen R, Berry SH, Hope ME, Murray GI, Mukhopadhya I, et al. Enterohepatic helicobacter in ulcerative colitis: Potential pathogenic entities? PLoS One 2011;6:e17184.
43. Triantafillidis JK, Gikas A, Apostolidiss N, Merikas E, Mallass E, Peros G. The low prevalence of Helicobacter infection in patients with inflammatory bowel disease could be attributed to previous antibiotic treatment. Am J Gastroenterol 2003;98:1213–4.
44. Khan KJ, Ullman TA, Ford AC, Abreu MT, Abadir A, Marshall JK, et al. Antibiotic therapy in inflammatory bowel disease: A systematic review and meta-analysis. Am J Gastroenterol 2011;106:661–73.
45. Maeng L, Lee A, Choi K, Kang CS, Kim KM. Granulomatous gastritis: A clinicopathologic analysis of 18 biopsy cases. Am J Surg Pathol 2004;28:941–5.
46. Torrente F, Anthony A, Heuschkel RB, Thomson MA, Ashwood P, Murch SH, et al. Focal-enhanced gastritis in regressive autism with features distinct from Crohn’s and helicobacter pylori gastritis. Am J Gastroenterol 2004;99:598–605.
47. Jovanovic IR, Milosavjevic TN, Jankovic GP, Micev MM, Dugalic PD, Saranovic D, et al. Clinical onset of the Crohn’s disease after eradication therapy of helicobacter pylori infection. Does helicobacter pylori infection interact with natural history of inflammatory bowel diseases? Med Sci Monit 2001;7:137–41.
48. Tursi A. Onset of Crohn’s disease after Helicobacter pylori eradication. Inflamm Bowel Dis 2006;12:1008–9.
49. Papamichael K, Konstantopoulos P, Mantzaris GJ. Helicobacter pylori infection and inflammatory bowel disease: Is there a link? World J Gastroenterol 2014;20:6374–85.
50. Sonnenberg A, Genta RM. Low prevalence of helicobacter pylori infection among patients with inflammatory bowel disease. Aliment Pharmacol Ther 2012;35:469–76.

APA	Varas M, Muñoz Agel F, Sánchez-Vizcaíno Mengual E (2019). Eradication of Helicobacter pylori in Patients with Inflammatory Bowel Disease for Prevention of Recurrences - Impact on the Natural History of the Disease. , 59 - 65. 10.14744/ejmo.2018.0058
Chicago	Varas Modesto,Muñoz Agel Fernando,Sánchez-Vizcaíno Mengual Elena Eradication of Helicobacter pylori in Patients with Inflammatory Bowel Disease for Prevention of Recurrences - Impact on the Natural History of the Disease. (2019): 59 - 65. 10.14744/ejmo.2018.0058
MLA	Varas Modesto,Muñoz Agel Fernando,Sánchez-Vizcaíno Mengual Elena Eradication of Helicobacter pylori in Patients with Inflammatory Bowel Disease for Prevention of Recurrences - Impact on the Natural History of the Disease. , 2019, ss.59 - 65. 10.14744/ejmo.2018.0058
AMA	Varas M,Muñoz Agel F,Sánchez-Vizcaíno Mengual E Eradication of Helicobacter pylori in Patients with Inflammatory Bowel Disease for Prevention of Recurrences - Impact on the Natural History of the Disease. . 2019; 59 - 65. 10.14744/ejmo.2018.0058
Vancouver	Varas M,Muñoz Agel F,Sánchez-Vizcaíno Mengual E Eradication of Helicobacter pylori in Patients with Inflammatory Bowel Disease for Prevention of Recurrences - Impact on the Natural History of the Disease. . 2019; 59 - 65. 10.14744/ejmo.2018.0058
IEEE	Varas M,Muñoz Agel F,Sánchez-Vizcaíno Mengual E "Eradication of Helicobacter pylori in Patients with Inflammatory Bowel Disease for Prevention of Recurrences - Impact on the Natural History of the Disease." , ss.59 - 65, 2019. 10.14744/ejmo.2018.0058
ISNAD	Varas, Modesto vd. "Eradication of Helicobacter pylori in Patients with Inflammatory Bowel Disease for Prevention of Recurrences - Impact on the Natural History of the Disease". (2019), 59-65. https://doi.org/10.14744/ejmo.2018.0058

APA	Varas M, Muñoz Agel F, Sánchez-Vizcaíno Mengual E (2019). Eradication of Helicobacter pylori in Patients with Inflammatory Bowel Disease for Prevention of Recurrences - Impact on the Natural History of the Disease. Eurasian Journal of Medicine and Oncology, 3(1), 59 - 65. 10.14744/ejmo.2018.0058
Chicago	Varas Modesto,Muñoz Agel Fernando,Sánchez-Vizcaíno Mengual Elena Eradication of Helicobacter pylori in Patients with Inflammatory Bowel Disease for Prevention of Recurrences - Impact on the Natural History of the Disease. Eurasian Journal of Medicine and Oncology 3, no.1 (2019): 59 - 65. 10.14744/ejmo.2018.0058
MLA	Varas Modesto,Muñoz Agel Fernando,Sánchez-Vizcaíno Mengual Elena Eradication of Helicobacter pylori in Patients with Inflammatory Bowel Disease for Prevention of Recurrences - Impact on the Natural History of the Disease. Eurasian Journal of Medicine and Oncology, vol.3, no.1, 2019, ss.59 - 65. 10.14744/ejmo.2018.0058
AMA	Varas M,Muñoz Agel F,Sánchez-Vizcaíno Mengual E Eradication of Helicobacter pylori in Patients with Inflammatory Bowel Disease for Prevention of Recurrences - Impact on the Natural History of the Disease. Eurasian Journal of Medicine and Oncology. 2019; 3(1): 59 - 65. 10.14744/ejmo.2018.0058
Vancouver	Varas M,Muñoz Agel F,Sánchez-Vizcaíno Mengual E Eradication of Helicobacter pylori in Patients with Inflammatory Bowel Disease for Prevention of Recurrences - Impact on the Natural History of the Disease. Eurasian Journal of Medicine and Oncology. 2019; 3(1): 59 - 65. 10.14744/ejmo.2018.0058
IEEE	Varas M,Muñoz Agel F,Sánchez-Vizcaíno Mengual E "Eradication of Helicobacter pylori in Patients with Inflammatory Bowel Disease for Prevention of Recurrences - Impact on the Natural History of the Disease." Eurasian Journal of Medicine and Oncology, 3, ss.59 - 65, 2019. 10.14744/ejmo.2018.0058
ISNAD	Varas, Modesto vd. "Eradication of Helicobacter pylori in Patients with Inflammatory Bowel Disease for Prevention of Recurrences - Impact on the Natural History of the Disease". Eurasian Journal of Medicine and Oncology 3/1 (2019), 59-65. https://doi.org/10.14744/ejmo.2018.0058